Patients who experience adverse ocular effects with bisphosphonates have a notably higher risk for osteonecrosis than those who do not experience such events, a large cohort study shows.
Data suggest a protective association of bisphosphonates against having a kidney stone diagnosis or procedure. Patients receiving bisphosphonates for osteoporosis treatment are less likely to have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback